Navigation Links
Neuronetrix Announces Preliminary Alzheimer's Study Results at the Society for Neuroscience Conference
Date:12/8/2008

LOUISVILLE, Ky., Dec. 8 /PRNewswire/ -- Last week, at the Society for Neuroscience Conference in Washington DC, Neuronetrix announced preliminary results from a clinical study of their COGNISION(TM) System to diagnose Alzheimer's disease. The study was performed with Alzheimer's patients at the University of Kentucky's Sanders-Brown Center for Aging.

The COGNISION(TM) System uses event-related potentials (ERP) to record brain activity while the patient listens to a sequence of sounds. Subjects with Alzheimer's process auditory information differently than healthy individuals and that difference can be detected with the test.

The ability of the ERP method to diagnose Alzheimer's disease has been demonstrated in scientific studies at several research laboratories around the world. In a scientific paper published in 2007, Neuronetrix collaborators Drs. Robi Polikar, et al, reported that their ERP classification accuracy "exceeded that of the trained community clinic physicians, and closely approached the gold standard performance of the university hospital-based clinic evaluation."

This phase of the study was primarily performed to evaluate the COGNISION(TM) System in a real-world clinical setting to test ease of use, patient tolerance, and most importantly, data quality.

"Clinical usability and technical performance were major milestones in our study at the Sanders-Brown Center." "The system exceeded our expectations in terms of data quality and we demonstrated the test could be efficiently performed on real Alzheimer's patients." K.C. Fadem, Neuronetrix, Inc.

The next clinical study phase for Neuronetrix will be to test the COGNISION(TM) System in a multi-center trial on patients who have been diagnosed with Alzheimer's disease using a rigorous diagnostic protocol. This protocol will be similar to that used in the Alzheimer's Disease Neuroimaging Initiative (ADNI), a large international study sponsored by the US National Institutes of Health (NIH).

The ADNI protocol uses psychometric testing, magnetic resonance imaging (MRI), and cerebrospinal fluid analysis (CSF) to accurately characterize several aspects of Alzheimer's disease. Neuronetrix will use these same tests to correlate with the COGNISION(TM) ERP results.

"We want to compare our COGNISION(TM) System with the most advanced diagnostic methods possible to clearly demonstrate the system's capabilities." Dr. John Barker, Chairman, Neuronetrix, Inc.

Neuronetrix is currently working with several NIH Center's of Excellence in the US and a center in Europe to organize the study which is expected to begin in the first quarter of 2009.

About Alzheimer's Disease

Alzheimer's disease is a chronic neurodegenerative disease of the brain which eventually leads to death. Today, Alzheimer's disease affects over 5 million Americans with 500,000 new cases reported each year. The Center for Disease Control recently reported that Alzheimer's disease is the 7th leading cause of death in the US. Those affected by Alzheimer's disease survive only about half as long as those unaffected and of similar age. In 2005, Medicare/Medicaid spending totaled $112 billion on beneficiaries with Alzheimer's and other dementias.

For information: http://www.neuronetrix.com .


'/>"/>
SOURCE Neuronetrix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets ... Market 2017-2021" report to their offering. ... The global energy-based aesthetic devices market ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, ... from industry experts. The report covers the market landscape and its ...
(Date:3/29/2017)... Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving ... Carmine N. Stengone , president and chief executive officer, will present ... th Annual Healthcare Conference on Wednesday, April 5, 2017, at ... Hotel in New York City . ... ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced the ... Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in Italy ... value in 2016. There are currently three proton therapy centers in ... more patients. In Italy , the first patients were ...
Breaking Medicine Technology:
(Date:3/30/2017)... Philadelphia, PA (PRWEB) , ... March 30, 2017 ... ... Wharton School is expanding its educational offerings of corporate finance programs to address ... a new program, will help executives increase their knowledge of sophisticated corporate finance ...
(Date:3/30/2017)... ... March 30, 2017 , ... ... live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” with noted ... 1:00 pm ET. This conference discusses strategies to prevent readmissions in light of ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... MD (PRWEB) , ... March 30, 2017 , ... CHARM ... Charm City Run has announced that Mercy Medical Center will serve as the official ... the Mid-Atlantic region. On Sunday, June 25, 2017, thousands of women will walk or ...
(Date:3/29/2017)... ... 2017 , ... Wells Pharmacy Network, a proud A4M Platinum ... World Congress, in Hollywood Florida April 6-8, 2017. , Ben David, CEO of ... in the training of physicians, scientists, and members of the public on anti-aging ...
Breaking Medicine News(10 mins):